Intestinal Imaging Articles
-
Rani is Opening Doors in Biosimilars, Challenging Humira and Others
San Jose-based Rani Therapeutics reported its fourth quarter and full-year 2021 financial results, as well as several corporate updates. The company hit major milestones this year, including the recent launch of the RaniPill High Capacity, which opens doors for significant developments in biosimilars. Rani has been on the radar of major life science investors for years. The company caught ...
-
Rani developing technology for oral delivery of injectable biologics
(NASDAQ:RANI) is developing a disruptive technology to solve the problem of converting biologic injectable drugs, including antibodies, peptides and proteins, into oral therapies with its RaniPill that bypasses destruction in the stomach to deliver its payload to the vascular intestinal wall in the GI tract. “This is not a new idea, although previous attempts were based on chemistry and ...
-
Why Supplementing Digestive Enzymes Is Necessary for Most People?
Enzymes are proteins with catalytic functions in organisms. The distinguishing feature of enzymes is that they have a high degree of catalytic function and specificity, and the activity of enzymes can be adjusted, which is closely related to the conversion of different energy forms. Up to now, there are nearly 2,000 known enzymes. Digestive enzyme is one of them. It is mainly secreted by the ...
-
Rani Therapeutics offers breakthrough capsule for patients with chronic conditions
Rani Therapeutics offers a breakthrough capsule, the RaniPill which could change the way patients with chronic conditions take medication by eliminating the need for painful injections. Rani Therapeutics is a clinical-stage biotherapeutics company offering an alternative to painful injections for patients with chronic conditions such as neuroendocrine tumours(NETS). The company based in ...
-
Rani Therapeutics prices $73M IPO for robotic drug-delivery pill tech
Rani Therapeutics Holdings (NSDQ:RANI), developer of a robotic drug-delivery pill system, generated $73.3 million in its underwritten initial public offering (IPO) of Class A common stock. The San Jose, Calif.–based company’s IPO of 6.7 million shares priced at $11 a share, generating gross proceeds of $73.3 million. The company initially targeted an IPO worth approximately $100 ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you